SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK, April 12, 2020

The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On April 1, 2020, the Food and Drug Administration ("FDA") issued a voluntary recall of Sanofi's Zantac product, a prescription and over-the-counter heartburn drug.  Specifically, the FDA cited findings that the amount of N-Nitrosodimethylamine (NDMA), believed to be a carcinogen when ingested at higher levels, in Zantac increases over time and when the drug is stored at higher than room temperatures.  On this news, Sanofi's stock price fell sharply, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com